Compare Nokia Corp (NOK) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Nokia Corp trades at $10.73 (market cap $59.77B), while State Street SPDR S&P Biotech ETF trades at $159.8. The key difference: Nokia Corp pays a 1.53% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Nokia Corp nearer its low. Which is the better fit depends on your goals.
| NOK | XBI | |
|---|---|---|
Market Cap | $59.77B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $16.83 | $169.55 |
52-Week Low | $4.51 | $93.43 |
Enterprise Value | $57.71B | — |
Dividend Yield | 1.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.66, up 6.18% on the day, supported by a bullish technical signal and positive momentum from AI-driven network infrastructure growth. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026, with revenue stabilizing around $20 billion annually. Analyst sentiment is predominantly bullish, with 61.5% recommending Buy, amid news of its return to the Euro Stoxx 50 index and expansion in Saudi AI research.
The outlook is cautiously optimistic, driven by AI and cloud demand, but risks include competitive pressures, volatile cash flow, and high valuation multiples. Investment opportunity hinges on execution of growth initiatives, while shareholders face exposure to telecom sector volatility and margin challenges.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
